In last trading session, Verve Therapeutics Inc (NASDAQ:VERV) saw 1.32 million shares changing hands with its beta currently measuring 1.79. Company’s recent per share price level of $6.36 trading at -$0.05 or -0.78% at ring of the bell on the day assigns it a market valuation of $538.47M. That closing price of VERV’s stock is at a discount of -216.35% from its 52-week high price of $20.12 and is indicating a premium of 32.39% from its 52-week low price of $4.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.25 million shares which gives us an average trading volume of 1.36 million if we extend that period to 3-months.

For Verve Therapeutics Inc (VERV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.20. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.7 in the current quarter.

Verve Therapeutics Inc (NASDAQ:VERV) trade information

Upright in the red during last session for losing -0.78%, in the last five days VERV remained trading in the green while hitting it’s week-highest on Wednesday, 11/06/24 when the stock touched $6.36 price level, adding 6.61% to its value on the day. Verve Therapeutics Inc’s shares saw a change of -54.38% in year-to-date performance and have moved 10.99% in past 5-day. Verve Therapeutics Inc (NASDAQ:VERV) showed a performance of 39.17% in past 30-days. Number of shares sold short was 17.44 million shares which calculate 14.14 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 14 to the stock, which implies a rise of 54.57% to its current value. Analysts have been projecting 13 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -104.4% in reaching the projected high whereas dropping to the targeted low would mean a loss of -104.4% for stock’s current value.

Verve Therapeutics Inc (VERV) estimates and forecasts

Statistics highlight that Verve Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 75.10% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.28M for the same. And 5 analysts are in estimates of company making revenue of 3.17M in the next quarter. Company posted 5.14M and 5.7M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -67.06% during past 5 years.

Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders

Insiders are in possession of 1.78% of company’s total shares while institution are holding 86.21 percent of that, with stock having share float percentage of 87.77%. Investors also watch the number of corporate investors in a company very closely, which is 86.21% institutions for Verve Therapeutics Inc that are currently holding shares of the company. ALPHABET INC. is the top institutional holder at VERV for having 12.35 million shares of worth $60.26 million. And as of 2024-06-30, it was holding 14.8546 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 6.62 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.9632 of outstanding shares, having a total worth of $32.31 million.